Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score

INTRODUCTION: Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positive breast carcinoma, and are known to induce bone density loss and increase the risk of fractures. The current standard-of-care screening tool for fracture risk is bone mineral density (B...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariotti, Veronica, Page, David B., Davydov, Oksana, Hans, Didier, Hudis, Clifford A., Patil, Sujata, Kunte, Siddharth, Girotra, Monica, Farooki, Azeez, Fornier, Monica N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469247/
https://www.ncbi.nlm.nih.gov/pubmed/28626628
http://dx.doi.org/10.1016/j.jbo.2016.10.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469247/
https://www.ncbi.nlm.nih.gov/pubmed/28626628
http://dx.doi.org/10.1016/j.jbo.2016.10.004

Ejemplares similares